Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2009
10/22/2009US20090264382 Methods for Treating Hematopoietic Neoplasms
10/22/2009US20090264381 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/22/2009US20090264377 Anti-neoplastic compositions comprising extracts of black cohosh
10/22/2009US20090264371 Antiproliferative peptides and antibodies for their detection
10/22/2009US20090264364 Genes implicated in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications
10/22/2009US20090264349 CD30 Ligand
10/22/2009US20090264345 Macrocyclic peptides and methods for making and using them
10/22/2009US20090264343 Method of producing fr901228
10/22/2009US20090263883 Recombinant Parainfluenza Virus Expression Systems And Vaccines Comprising Heterologous Antigens Derived From Respiratory Syncytial Virus
10/22/2009US20090263852 Nonapoptotic forms of cell death and methods of modulation
10/22/2009US20090263847 Lsr receptor, its activity, its cloning and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications
10/22/2009US20090263818 Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme
10/22/2009US20090263521 Composition for the treatment of cancers and inhibition of metastasis containing extracts or fractions of the magnolia obovata
10/22/2009US20090263516 Plant Extract Composition and Their Use to Modulate Cellular Activity
10/22/2009US20090263512 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
10/22/2009US20090263504 Methods and compositions for promoting activity of anti-cancer therapies
10/22/2009US20090263486 Nanoparticle-stabilized capsule formulation for treatment of inflammation
10/22/2009US20090263485 Targeted hollow gold nanostructures and methods of use
10/22/2009US20090263425 Methods of stimulating an immune response against prostate specific antigen
10/22/2009US20090263409 Cancer antigen peptide formulations
10/22/2009US20090263404 Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor
10/22/2009US20090263402 Growth Differentiation Factor-11
10/22/2009US20090263401 USES OF IL-174 ANTAGONISTS FOR INHIBITING A Th2 IMMUNE RESPONSE
10/22/2009US20090263399 Method for establishing the sensitivity of tumours to capecitabin and test kit
10/22/2009US20090263398 Pharmaceutical combinations
10/22/2009US20090263397 Combination anti-cancer therapy
10/22/2009US20090263396 Inhibitors of t-darpp for use in combination anti-cancer therapies
10/22/2009US20090263395 Genes and polypeptides relating to breast cancers
10/22/2009US20090263393 Methods of using(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4 -oxo-1-(2-thiazolyl)- 1,8-naphthyridine-3-carboxylic acid for treatment of cancer
10/22/2009US20090263390 Method of treating cancer by co-administration of anticancer agents
10/22/2009US20090263383 Antibodies to angiogenesis inhibiting domains of CD148
10/22/2009US20090263377 Il-32b-targeted diagnosis and therapy
10/22/2009US20090263358 autologously transplanting hematopoietic progenitor cell population which has been treated with antibody (monoclonal, chimeric, or humanized; not conjugated to toxin or cytolytic agent); radiotherapy
10/22/2009US20090263354 Compositions and siRNAs for inhibiting C/EBPbeta
10/22/2009US20090263353 Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles
10/22/2009US20090263349 Methods and compositions for inhibiting angiogenesis
10/22/2009US20090263328 Fluorescence observation apparatus and fluoroscopy method
10/22/2009US20090263320 Peptide-Based Compounds
10/22/2009US20090263318 Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
10/22/2009DE102008019907A1 Pyridazinonderivate Pyridazinone derivatives
10/22/2009CA2721838A1 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
10/22/2009CA2721837A1 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
10/22/2009CA2721666A1 Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
10/22/2009CA2721595A1 Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide andmethods of use therefor
10/22/2009CA2721506A1 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
10/22/2009CA2721467A1 Spirocyclic derivatives as histone deacetylase inhibitors
10/22/2009CA2721339A1 Activating agent for peroxisome proliferator activated receptor
10/22/2009CA2721333A1 Novel lipid formulations for nucleic acid delivery
10/22/2009CA2721229A1 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
10/22/2009CA2721191A1 Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
10/22/2009CA2721169A1 Prostate specific membrane antigen antibodies and antigen binding fragments
10/22/2009CA2721032A1 Anti-areg/hb-egf antibodies and treatment
10/22/2009CA2721019A1 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
10/22/2009CA2720671A1 Compositions and methods for preparing and using same
10/22/2009CA2693001A1 Compositions and methods for treating pathologic angiogenesis and vascular permeability
10/21/2009EP2110669A1 Methods for the identification of allo-antigens and their use for cancer therapy and transplantation
10/21/2009EP2110384A1 Hepatopoietin and use thereof
10/21/2009EP2110377A1 Spirocyclic derivatives as histone deacetylase inhibitors
10/21/2009EP2110138A1 Dosages for treatment of anti-erbB2 antibodies
10/21/2009EP2110134A1 Cocoa extract compounds and methods for making and using the same
10/21/2009EP2110131A1 Anti-tumor composition comprising tissue-accumulating chitosan gel
10/21/2009EP2109612A2 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
10/21/2009EP2109608A1 Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
10/21/2009EP2109607A1 Pyrrolo[3, 2-a]pyridine derivatives for inhibiting ksp kinesin activity
10/21/2009EP2109605A2 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
10/21/2009EP2109604A1 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
10/21/2009EP2109462A1 Antitumor combination comprising a morpholinyl anthracycline and an antibody
10/21/2009EP2109460A1 Anti-kir antibodies, formulations, and uses thereof
10/21/2009EP2109455A2 Compositions and methods for stimulating an immune response
10/21/2009EP2109452A1 Use of a leukocyte diminishing or inactivating agent in combination with bacterially-mediated tumor treatment
10/21/2009EP2109448A2 Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
10/21/2009EP1971601B1 N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
10/21/2009EP1904471B1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
10/21/2009EP1781673B1 Selected fused heterocyclics and uses thereof
10/21/2009EP1776138B1 tRNA SYNTHETASE FRAGMENTS
10/21/2009EP1515724B1 Mitotic kinesin inhibitors
10/21/2009EP1513531B1 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
10/21/2009EP1463506B1 Substituted quinazoline derivatives as inhibitors of aurora kinases
10/21/2009EP1450750B1 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
10/21/2009EP1423413B1 Peptidic compounds selectively binding to p-selectin
10/21/2009EP1397386B1 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same
10/21/2009EP1392359B1 Specific binding proteins and uses thereof
10/21/2009EP1383778B1 Agonists and antagonists of sphingosine-1-phosphate receptors
10/21/2009EP1371373B1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/21/2009EP1280776B1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis
10/21/2009EP1169062B1 Heat stable coated colloidal iron oxides
10/21/2009EP1164991B1 Gels formed by the interaction of poly(aldehyde) with various substances
10/21/2009EP1162968B1 Epigallocatechin-gallate for inhibiting angiogenesis
10/21/2009EP1117672B1 Antisense modulation of survivin expression
10/21/2009CN101563366A Anti-NOTCH3 agonist antibodies and their use in the treatment of NOTCH3-related diseases
10/21/2009CN101563365A Anti-IL-6 monoclonal antibodies and uses thereof
10/21/2009CN101563351A Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
10/21/2009CN101563345A Pharmaceutical compounds
10/21/2009CN101563342A Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer
10/21/2009CN101563340A 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
10/21/2009CN101563339A 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as PI3K and MTOR inhibitors for the treatment of proliferative disorders
10/21/2009CN101563338A MAPK/ERK kinase inhibitors
10/21/2009CN101563336A Heterocyclic organic compounds for the treatment of in particular melanoma
10/21/2009CN101563090A Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
10/21/2009CN101560546A Application of Phosphatidylinositol4-kinase type II alpha PI4KIIalpha
1 ... 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 ... 2211